Adaptive Biotechnologies Corp (NAS:ADPT)
$ 3.31 -0.14 (-4.06%) Market Cap: 487.79 Mil Enterprise Value: 296.04 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 72/100

Adaptive Biotechnologies Corp at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 11:00PM GMT
Release Date Price: $7.94 (+8.62%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have the Adaptive team with us. We have Chad Robins, CEO, Co-Founder and Chairman; and Tycho Peterson, CFO. Thank you, guys, for joining us.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Thanks, Salveen and Goldman, for having us. Appreciate it.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Yes. So maybe to start here, Tycho, you recently completed your first year as CFO of Adaptive and joining Chad. And Chad, you've kind of implemented, in conjunction with Tycho, this change in strategy here. So when we take a snapshot of where we are today versus last year and your outlook for the forward, with regard to the changes that you've taken, where are you from an implementation stage at this point? And are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot